Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Dapirolizumab pegol
CD40 ligand inhibitor
Compared with
- Ocrelizumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
Number of cumulative Gd-enhancing lesions over 2 brain MRI scans at Week 8 and Week 12
MRI lesions
Other measures (1)
Secondary efficacy endpoints:
Who could take part
Relapsing MS
Inclusion: Key Inclusion Criteria: Exclusion: Key Exclusion Criteria:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate effect of BIIB133 versus placebo on key brain magnetic resonance imaging (MRI) outcomes.
Papers
Loading reviews and guidelines…
Related trials
- LTS18002
Phase 3 · Not yet recruiting
Still running
- FREXALT
Phase 3 · Running, not recruiting
Still running
- LITMUS
Not a drug-phase study · Completed (inferred)
Results posted, no main test reported
- SUSTAIN
Phase 3 · Stopped early
Stopped early
- ZEUS
Not a drug-phase study · Stopped
Stopped early
- MS-IL2
Phase 2 · Completed
Result in a paper, not read yet
History
Started
May 2020
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error